Korea's CrystalGenomics Evaluates Phase II Options For Super Bug Antibiotic Candidate
This article was originally published in PharmAsia News
Executive Summary
SEOUL - South Korea's CrystalGenomics recently wrapped up the second-round of Phase I clinical trials for its antibiotic candidate CG400549 in Europe